Biotech animals don't have the market value of biotech drugs and potential controversies loom large, but genetic screening technologies are already finding a market, and both cloned and transgenic animals may soon be on the menu. Alan Dove reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
01 April 2005
Nat. Biotechnol. 23, 283–285 (2005) On page 285, last column, paragraph 2, last line, the reduction in fecal phosphorus was reported as 30%. It should have read 70%.
References
International Chicken Genome Sequencing Consortium Nature, 432, 695–716 (2004).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Related external links
FAO/WHO Safety Assessment of Foods derived from Genetically Modified Animals
Rights and permissions
About this article
Cite this article
Dove, A. Clone on the range: What animal biotech is bringing to the table. Nat Biotechnol 23, 283–285 (2005). https://doi.org/10.1038/nbt0305-283
Issue Date:
DOI: https://doi.org/10.1038/nbt0305-283
This article is cited by
-
Erratum: Clone on the range: what animal biotech brings to the table
Nature Biotechnology (2005)
